DCST1 Inhibitors
DCST1 inhibitors are a diverse set of chemical compounds that restrain the functional activity of DCST1 by targeting various signaling pathways and cellular processes. For instance, 2-Bromohexadecanoic acid limits DCST1's functionality by disrupting protein palmitoylation, potentially affecting the protein's cellular location and activity if palmitoylation is necessary for DCST1's function. Similarly, LY 294002 and U0126 target the PI3K/Akt and MEK/ERK pathways, respectively, thereby attenuating signaling that could be requisite for DCST1's activation. In the case of protein kinase inhibition, Gö 6983 and Dasatinib inhibit PKC and tyrosine kinases, which may decrease DCST1 activity by altering the phosphorylation state that governs its activity. Additionally, Tyrphostin B42's inhibition of JAK2 and Bortezomib's prevention of proteasomal degradation may disrupt downstream signaling and turnover regulation of DCST1.
The inhibitors also modulate other cellular processes that could indirectly affect DCST1's activity. Cyclosporin A, by inhibiting calcineurin, may maintain a phosphorylation state unfavorable to DCST1's function, while Rp-8-Br-PET-cGMPS and L-NAME curtail the signaling mediated by PKG and nitric oxide synthesis, potentially altering DCST1's activity if it is regulated by these molecules. Verapamil's blockade of L-type calcium channels could inhibit calcium-dependent signaling pathways that are necessary for DCST1's function. Collectively, these inhibitors showcase the intricate network of cellular signaling and regulatory mechanisms that can be employed to diminish the activity of DCST1, each acting through distinct but converging biological pathways to achieve functional inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Bromohexadecanoic acid | 18263-25-7 | sc-251714 sc-251714A | 10 g 50 g | $53.00 $201.00 | 4 | |
By inhibiting the palmitoylation process, 2-Bromohexadecanoic acid diminishes the functional activity of DCST1. Palmitoylation is critical for the localization and activity of many transmembrane proteins; hence, the inhibition of this post-translational modification can indirectly decrease the functional activity of DCST1 if it relies on palmitoylation for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 inhibits the PI3K/Akt pathway, which is crucial for a myriad of cellular processes including metabolism, cell survival, and growth. If DCST1 function is regulated by signals from the PI3K/Akt pathway, LY 294002's inhibition would lead to a decrease in DCST1 activity by hindering the pathway's signaling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 acts by inhibiting Protein Kinase C (PKC), which plays a role in various signaling cascades. If DCST1 activity is modulated by PKC-mediated signaling, the inhibition of PKC could diminish DCST1 activity by reducing the signal transduction that would otherwise activate DCST1. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits the phosphatase activity of calcineurin. If DCST1 function is regulated by dephosphorylation events mediated by calcineurin, then the inhibition of calcineurin would result in reduced activity of DCST1 due to maintained phosphorylation states that inhibit its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib targets multiple tyrosine kinases, which are part of signaling pathways that regulate cell division and survival. If the activity of DCST1 is tyrosine phosphorylation-dependent, then dasatinib would decrease DCST1 activity by inhibiting the kinases that would phosphorylate and activate DCST1. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 inhibits the Janus Kinase 2 (JAK2), which is involved in the signaling pathways of certain growth factors and cytokines. Should DCST1 activity be influenced by JAK-STAT signaling, Tyrphostin B42 would diminish DCST1 activity by blocking this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib impedes the proteasome's ability to degrade misfolded or ubiquitin-tagged proteins. If DCST1 requires proteasome-mediated degradation for regulation, then bortezomib could lead to decreased functional activity of DCST1 by preventing its turnover. | ||||||
Rp-8-Br-PET-cGMPs | 185246-32-6 | sc-215820 sc-215820A | 1 mg 5 mg | $343.00 $1348.00 | 1 | |
This inhibitor targets cGMP-dependent protein kinase (PKG), which signals in various pathways including vasodilation and neuronal signaling. If DCST1 is regulated by PKG-mediated signaling, then its inhibition would diminish the functional activity of DCST1. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil blocks L-type calcium channels, thereby inhibiting the influx of calcium ions which are crucial for many signaling pathways. If DCST1 relies on calcium signaling for its activity, then verapamil would decrease DCST1 activity by blocking this pathway. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME inhibits the synthesis of nitric oxide, a signaling molecule involved in a variety of cellular processes. If DCST1 activity is modulated by nitric oxide signaling, then inhibiting its synthesis would diminish the functional activity of DCST1. | ||||||